January 28, 2026
1 min read

Cellares’ series D round draws $257M as cell therapy contractor takes operations global

With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, raising $257 million in a series D round.

Leave a Reply

Your email address will not be published.

Previous Story

Antheia seals 2nd series C funding close, hitting more than $175M in a year

Next Story

From the community | MAHA is worsening nutrition insecurity — ‘Food is Medicine’ can do better

Previous Story

Antheia seals 2nd series C funding close, hitting more than $175M in a year

Next Story

From the community | MAHA is worsening nutrition insecurity — ‘Food is Medicine’ can do better

Latest from Blog

Go toTop